The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation
Open accessAbstract
Purpose: Intracerebral microdialysis (ICMD) is an accepted method for monitoring changes in neurochemistry from acute brain injury. The goal of this pilot study was to determine the feasibility of using ICMD to examine the neuropharmacokinetics of temozolomide in brain interstitium following oral administration. Experimental Design: Patients with primary or metastatic brain tumors had a microdialysis catheter placed in peritumoral brain tissue at the time of surgical debulking. Computerized tomography scan confirmed the catheter location. Patients received a single oral dose of temozolomide (150 mg/m2) on the first postoperative day, serial plasma and ICMD samples were collected over 24 hours, and temozolomide concentrations were determined by tandem mass spectrometry. Results: Nine patients were enrolled. Dialysate and plasma samples were successfully collected from seven of the nine patients. The mean temozolomide areas under the concentration-time curve (AUC) in plasma and brain interstitium were 17.1 and 2.7 g/mL hour, with an average brain interstitium/plasma AUC ratio of 17.8. The mean peak temozolomide concentration in the brain was 0.6 0.3 g/mL, and the mean time to reach peak level in brain was 2.0 0.8 hours. Conclusions: The use of ICMD to measure the neuropharmacokinetics of systemically administered chemotherapy is safe and feasible. Concentrations of temozolomide in brain interstitium obtained by ICMD are consistent with published data obtained in a preclinical ICMD model, as well as from clinical studies of cerebrospinal fluid. However, the delayed time required to achieve maximum temozolomide concentrations in brain suggests that current chemoradiation regimens may be improved by administering temozolomide 2 to 3 hours before radiation. (Clin Cancer Res 2009;15(22):70928)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain
During, M. J., & Spencer, D. D. (1993) · The Lancet · doi:10.1016/0140-6736(93)90754-5 · Cited by 902
Vespa, P., Bergsneider, M., Hattori, N., Wu, H.-M., Huang, S.-C., Martin, N. A., Glenn, T. C., McArthur, D. L., & Hovda, D. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600073 · Cited by 638
Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 518
Vespa, P., Boonyaputthikul, R., McArthur, D. L., Miller, C., Etchepare, M., Bergsneider, M., Glenn, T., Martin, N., & Hovda, D. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000201875.12245.6f · Cited by 343
Vespa, P. M., McArthur, D., O'Phelan, K., Glenn, T., Etchepare, M., Kelly, D., Bergsneider, M., Martin, N. A., & Hovda, D. A. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000076701.45782.ef · Cited by 342
Goodman, J. C., Valadka, A. B., Gopinath, S. P., Uzura, M., & Robertson, C. S. (1999) · Critical Care Medicine · doi:10.1097/00003246-199909000-00041 · Cited by 266
Methodological issues in microdialysis sampling for pharmacokinetic studies
de Lange, E. C. M., de Boer, A. G., & Breimer, D. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00107-1 · Cited by 264
Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V, & Cutler, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690802 · Cited by 208
Bedside microdialysis: A tool to monitor cerebral metabolism in subarachnoid hemorrhage patients?*
Sarrafzadeh, A. S., Sakowitz, O. W., Kiening, K. L., Benndorf, G., Lanksch, W. R., & Unterberg, A. W. (2002) · Critical Care Medicine · doi:10.1097/00003246-200205000-00018 · Cited by 193
Cited by
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery
Appelboom, G., Detappe, A., LoPresti, M., Kunjachan, S., Mitrasinovic, S., Goldman, S., Chang, S. D., & Tillement, O. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now137 · Cited by 340
Stepanenko, A. A., & Dmitrenko, V. V. (2015) · Gene · doi:10.1016/j.gene.2015.08.009 · Cited by 315
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 312
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence
Auffinger, B., Spencer, D., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1051968 · Cited by 292
Metadata
- Authors
- Portnow, J., Badie, B., Chen, M., Liu, A., Blanchard, S., & Synold, T. W.
- Venue
- Clinical Cancer Research
- Published
- 2009-11-11
- Volume
- 15
- Issue
- 22
- Pages
- 7092-7098
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2134466068
- Cited by
- 255
- References
- 23
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1349
- The paper
- Portnow, J., Badie, B., Chen, M., Liu, A., Blanchard, S., & Synold, T. W. (2009). The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1349
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.